Novo Nordisk's Oral Wegovy: FDA-Approved Weight Loss Pill for Obesity Treatment
The Food and Drug Administration has given the green light to Novo Nordisk's oral version of the weight loss drug Wegovy, marking the first GLP-1 pill approved for obesity treatment. This approval opens up the possibility for more Americans to access this highly effective treatment, which also helps reduce cardiovascular risks. Novo is set to launch the drug in January, with the highest dose leading to significant weight loss in patients. The pill is expected to be more convenient than the injectable version and does not require cold storage.
Novo's approval of the oral Wegovy comes at a time when the company is facing competition in the obesity market. The oral pill is made up of peptides, which are large molecules that require a substantial amount of pharmaceutical ingredients to be effective. Patients need to take the pill at least 30 minutes before eating in the morning. Meanwhile, Eli Lilly is awaiting FDA approval for its own GLP-1 pill, orforglipron, which is a small molecule and may be easier to manufacture. However, orforglipron did not show as much efficacy in trials as oral Wegovy.
The pricing of these weight loss pills will play a crucial role in determining demand. Novo and Lilly have agreed to sell their pills at $150 a month for the lowest dose through direct-to-consumer channels. The companies have not disclosed the pricing for higher doses or for insurance coverage. The approval of the oral Wegovy pill could potentially boost Novo's market share and provide more options for Americans seeking effective weight loss treatments.